Third Party Agreements - Additional Information (Details) - USD ($) $ in Millions |
3 Months Ended | |
---|---|---|
Jan. 28, 2022 |
Mar. 31, 2023 |
|
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] | ||
Related to project initiation fees | $ 1.0 | |
License agreement termination description | twelve (12) years | |
Regeneron Pharmaceuticals, Inc. | ||
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] | ||
Revenue recognized | $ 5.0 | |
Exercise Fee Paid | $ 20.0 | 20.0 |
Licence agreement additional revenue recognised | 25.0 | |
Non refundable upfront payment received | 25.0 | |
Additional payment for research funding received | 20.0 | |
Regeneron Pharmaceuticals, Inc. | Maximum | ||
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] | ||
Licence agreement additional amount payable of option exercise fees | $ 80.0 |